Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
Covered in this story
Analyst targets on Kymera Therapeutics Inc
- Raymond James: $109 → $140 by Oct 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $KYMR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kymera Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.